Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - norethisterone 0.35mg;  ;   - tablet - 0.35 mg - active: norethisterone 0.35mg     excipient: lactose monohydrate magnesium stearate maize starch povidone - noriday is indicated for oral contraception in women for whom oestrogens may not be appropriate.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sandoz gmbh - rifampicin - capsule - 300mg milligram

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sandoz gmbh - rifampicin - capsule - 150mg milligram

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sandoz gmbh - rifampicin isoniazid - coated tablets - 300/150mg milligram

Singapore - englanti - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - sulpiride - capsule - 50 mg

Singapore - englanti - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - sulpiride - tablet - 200 mg

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - baclofen 0.5 mg/ml - solution for infusion - 0.5 mg/ml - active: baclofen 0.5 mg/ml excipient: sodium chloride water for injection - intrathecal baclofen is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - baclofen 2 mg/ml - solution for infusion - 2 mg/ml - active: baclofen 2 mg/ml excipient: sodium chloride water for injection - intrathecal baclofen is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - baclofen 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: baclofen 0.05 mg/ml excipient: sodium chloride water for injection - intrathecal baclofen is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - baclofen, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.